Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:44:36 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Q:GALT - GALECTIN THERAPEUTICS INC - http://www.galileot.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GALT - Q0.12.98·3.790.13.45-0.05-1.4173.95601,4413.56  3.72  3.454.2684  1.2816:00:01Apr 0915 min RT 2¢

Recent Trades - Last 10 of 1441
Time ETExPriceChangeVolume
16:00:01Q3.45-0.053,583
16:00:01Q3.45-0.05155
16:00:01Q3.45-0.05113
16:00:01Q3.45-0.052
16:00:01Q3.45-0.0512
16:00:01Q3.45-0.0573
16:00:01Q3.45-0.0538
16:00:01Q3.45-0.05986
16:00:01Q3.45-0.052
16:00:01Q3.45-0.0553

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-09 08:00U:GALTNews ReleaseGalectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
2024-03-29 08:00U:GALTNews ReleaseGalectin Therapeutics Reports 2023 Financial Results and Provides Business Update
2024-03-12 08:00U:GALTNews ReleaseGalectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
2023-11-13 08:46U:GALTNews ReleaseUPDATE ¢ € “ Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
2023-11-13 08:00U:GALTNews ReleaseGalectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
2023-11-03 08:00U:GALTNews ReleaseGalectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting ¢ „ ¢ 2023, Hosted by the AASLD
2023-10-23 08:00U:GALTNews ReleaseGalectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023
2023-10-12 08:00U:GALTNews ReleaseGalectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors
2023-10-03 08:00U:GALTNews ReleaseGalectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Live
2023-09-26 08:00U:GALTNews ReleaseGalectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
2023-09-11 08:00U:GALTNews ReleaseGalectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023
2023-09-07 12:00U:GALTNews ReleaseGalectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
2023-08-14 08:00U:GALTNews ReleaseGalectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update
2023-05-15 08:00U:GALTNews ReleaseGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update